|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Securities, at fair value(1)(2) | ||||||||||||||||||||
| Loans, at fair value(1)(2) | ||||||||||||||||||||
| Loan commitments, at fair value | ||||||||||||||||||||
| Forward MSR-related investments, at fair value(1) | ||||||||||||||||||||
| Mortgage servicing rights, at fair value | ||||||||||||||||||||
| Investments in unconsolidated entities, at fair value(1) | ||||||||||||||||||||
| Real estate owned(1)(2) | ||||||||||||||||||||
| Financial derivatives—assets, at fair value | ||||||||||||||||||||
| Reverse repurchase agreements | ||||||||||||||||||||
| Securities for Reverse Repurchase Agreements | ||||||||||||||||||||
| Due from brokers | ||||||||||||||||||||
| Investment related receivables(1) | ||||||||||||||||||||
| Other assets(1) | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Securities sold short, at fair value | ||||||||||||||||||||
| Repurchase agreements(1) | ||||||||||||||||||||
| Reverse mortgage loans | ||||||||||||||||||||
| Total repurchase agreements(1) | ||||||||||||||||||||
| Financial derivatives—liabilities, at fair value | ||||||||||||||||||||
| Due to brokers | ||||||||||||||||||||
| Investment related payables | ||||||||||||||||||||
| Other secured borrowings(1) | ||||||||||||||||||||
| Other secured borrowings, at fair value(1) | ||||||||||||||||||||
| HMBS-related obligations, at fair value | ||||||||||||||||||||
| Unsecured borrowings, at fair value | ||||||||||||||||||||
| Base management fee payable to affiliate | ||||||||||||||||||||
| Incentive Fee Payable | ||||||||||||||||||||
| Dividends payable | ||||||||||||||||||||
| Interest payable(1) | ||||||||||||||||||||
| Accrued expenses and other liabilities(1) | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| ANALYSIS OF EQUITY: | ||||||||||||||||||||
| Preferred stock, 100,000,000 shares authorized; 9,200,089 and 13,800,089 shares issued and outstanding, and $230,002 and $345,002 aggregate liquidation preference, respectively | ||||||||||||||||||||
| Common stock, par value $0.001 per share, 300,000,000 shares authorized; 130,116,611 and 113,138,860 shares issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||||
| Retained earnings (accumulated deficit) | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Non-controlling interests(1) | ||||||||||||||||||||
| Total Equity | ||||||||||||||||||||
| Total Liabilities and Equity | ||||||||||||||||||||
| Preferred Stock, Shares Authorized | ||||||||||||||||||||
| Preferred Stock, Shares Outstanding | ||||||||||||||||||||
Loading...